P2RY12 and atrial fibrillation: Although there has been concern over greater bleeding risk increasing the potency of P2Y12 inhibition, recent evidence suggests, for example, ticagrelor may have similar safety to clopidogrel in patients at high risk of bleeding, such as those who are elderly with ST-elevation myocardial infarction [46], and low-dose prasugrel appears to be of comparable safety to clopidogrel when used in triple therapy (aspirin, P2Y12 inhibitor and anticoagulant) for patients with atrial fibrillation undergoing percutaneous coronary intervention [47].